

Tito R Mendoza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1496074/publications.pdf>

Version: 2024-02-01

65
papers

7,921
citations

172386

29
h-index

114418

63
g-index

67
all docs

67
docs citations

67
times ranked

9412
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of the shared decision-making process on lung cancer screening decisions. <i>Cancer Medicine</i> , 2022, 11, 790-797.	1.3	7
2	Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. <i>Cancer</i> , 2022, 128, 2736-2745.	2.0	8
3	A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. <i>Neuro-Oncology</i> , 2021, 23, 468-477.	0.6	28
4	Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. <i>Neuro-Oncology Practice</i> , 2021, 8, 417-425.	1.0	9
5	Associations between the gut microbiome and fatigue in cancer patients. <i>Scientific Reports</i> , 2021, 11, 5847.	1.6	24
6	Especially for neuro-oncologists—minimally important differences for the EORTC QLQ-C30 in glioma patients. <i>Neuro-Oncology</i> , 2021, 23, 1222-1222.	0.6	0
7	Shared Decision-Making for Lung Cancer Screening. <i>Chest</i> , 2021, 160, 330-340.	0.4	27
8	Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module. <i>Neuro-Oncology Practice</i> , 2021, 8, 137-147.	1.0	3
9	Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. <i>Supportive Care in Cancer</i> , 2020, 28, 261-269.	1.0	12
10	Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. , 2020, 8, e000931.		11
11	What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer. <i>JCO Oncology Practice</i> , 2020, 16, e1151-e1160.	1.4	8
12	The prevalence of altered body image in patients with primary brain tumors: an understudied population. <i>Journal of Neuro-Oncology</i> , 2020, 147, 397-404.	1.4	6
13	Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. <i>Lancet Oncology</i> , The, 2020, 21, e97-e103.	5.1	42
14	Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 787-793.	0.6	6
15	The Treatment-induced Neuropathy Assessment Scale (TNAS): a psychometric update following qualitative enrichment. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 15.	0.9	5
16	Quality of life impact of EUS in patients at risk for developing pancreatic cancer. <i>Endoscopic Ultrasound</i> , 2020, 9, 53.	0.6	6
17	New Developments in the Use of Patient-Reported Outcomes in Cancer Patients Undergoing Immunotherapies. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 335-339.	0.8	4
18	Concept domain validation and item generation for the Treatment-Induced Neuropathy Assessment Scale (TNAS). <i>Supportive Care in Cancer</i> , 2019, 27, 1021-1028.	1.0	8

#	ARTICLE	IF	CITATIONS
19	Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM). <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 34.	0.9	6
20	Assessment of baseline symptom burden in treatment-naïve patients with lung cancer: an observational study. <i>Supportive Care in Cancer</i> , 2019, 27, 3439-3447.	1.0	38
21	Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. <i>Lancet Oncology</i> , The, 2018, 19, e173-e180.	5.1	32
22	The Utility and Validity of the Alopecia Areata Symptom Impact Scale in Measuring Disease-Related Symptoms and their Effect on Functioning. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2018, 19, S41-S46.	0.8	16
23	Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors. <i>Radiotherapy and Oncology</i> , 2018, 126, 75-80.	0.3	19
24	Symptoms as Patient-Reported Outcomes in Cancer Patients Undergoing Immunotherapies. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 165-182.	0.8	3
25	Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM). <i>Quality of Life Research</i> , 2018, 27, 3229-3241.	1.5	11
26	Software for Administering the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study. <i>JMIR Human Factors</i> , 2018, 5, e10070.	1.0	20
27	Validation of the Persian Version of the Brief Pain Inventory (BPI-P) in Chronic Pain Patients. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 132-138.e2.	0.6	35
28	Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE. <i>Clinical Trials</i> , 2017, 14, 255-263.	0.7	58
29	Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old. <i>Radiation Oncology</i> , 2017, 12, 150.	1.2	25
30	Time for better presentation and analysis of adverse events. <i>Lancet Oncology</i> , The, 2016, 17, 553-554.	5.1	10
31	Linguistic validation of the Spanish version of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Supportive Care in Cancer</i> , 2016, 24, 2843-2851.	1.0	28
32	Validity and Reliability of the Indonesian Version of the Brief Fatigue Inventory in Cancer Patients. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 744-751.	0.6	20
33	Using a symptom-specific instrument to measure patient-reported daily functioning in patients with cancer. <i>European Journal of Cancer</i> , 2016, 67, 83-90.	1.3	16
34	Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Health and Quality of Life Outcomes</i> , 2016, 14, 24.	1.0	91
35	The symptom burden of treatment-naïve patients with head and neck cancer. <i>Cancer</i> , 2015, 121, 766-773.	2.0	56
36	Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale. <i>Journal of Pain</i> , 2015, 16, 1032-1043.	0.7	23

#	ARTICLE	IF	CITATIONS
37	Automated pain intervention for underserved minority women with breast cancer. <i>Cancer</i> , 2015, 121, 1882-1890.	2.0	27
38	Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>JAMA Oncology</i> , 2015, 1, 1051.	3.4	581
39	A Patient-Reported Outcome Measure for Symptoms and Symptom Burden of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2015, 126, 2094-2094.	0.6	8
40	Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Journal of the National Cancer Institute</i> , 2014, 106, dju244-dju244.	3.0	689
41	The Validity and Utility of the MD Anderson Symptom Inventory in Patients With Prostate Cancer: Evidence From the Symptom Outcomes and Practice Patterns (SOAPP) Data From the Eastern Cooperative Oncology Group. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 41-49.	0.9	31
42	Prognostic value of patient-reported symptom interference in patients with late-stage lung cancer. <i>Quality of Life Research</i> , 2013, 22, 2143-2150.	1.5	21
43	The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. <i>Cancer</i> , 2013, 119, 4333-4340.	2.0	235
44	Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 130, 323-328.	0.6	60
45	The Validity and Utility of the M. D. Anderson Symptom Inventory in Patients With Breast Cancer: Evidence From the Symptom Outcomes and Practice Patterns Data From the Eastern Cooperative Oncology Group. <i>Clinical Breast Cancer</i> , 2013, 13, 325-334.	1.1	33
46	Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. <i>Blood</i> , 2013, 122, 641-647.	0.6	91
47	A new symptom measure in gastrointestinal stomal tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, e17508-e17508.	0.8	1
48	Prospective, Observational Study of Pain and Analgesic Prescribing in Medical Oncology Outpatients With Breast, Colorectal, Lung, or Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1980-1988.	0.8	244
49	Changes in Pain and Other Symptoms in Patients With Painful Multiple Myeloma-Related Vertebral Fracture Treated With Kyphoplasty or Vertebroplasty. <i>Journal of Pain</i> , 2012, 13, 564-570.	0.7	37
50	Congruence of primary brain tumor patient and caregiver symptom report. <i>Cancer</i> , 2012, 118, 5026-5037.	2.0	27
51	Measuring the Symptom Burden of Lung Cancer: The Validity and Utility of the Lung Cancer Module of the M. D. Anderson Symptom Inventory. <i>Oncologist</i> , 2011, 16, 217-227.	1.9	99
52	Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). <i>Cancer</i> , 2010, 116, 2053-2063.	2.0	79
53	Impact of Cultural and Linguistic Factors on Symptom Reporting by Patients With Cancer. <i>Journal of the National Cancer Institute</i> , 2010, 102, 732-738.	3.0	44
54	Assessment of Fatigue in Cancer Patients and Community Dwellers: Validation Study of the Filipino Version of the Brief Fatigue Inventory. <i>Oncology</i> , 2010, 79, 112-117.	0.9	26

#	ARTICLE	IF	CITATIONS
55	Reliability and validity of the M. D. Anderson Symptom Inventoryâ€™Spine Tumor Module. <i>Journal of Neurosurgery: Spine</i> , 2010, 12, 421-430.	0.9	36
56	Development and Initial Validation of the Thyroid Cancer Module of the M. D. Anderson Symptom Inventory. <i>Oncology</i> , 2009, 76, 59-68.	0.9	46
57	Psychometric Testing of the MDASI-HF: A Symptom Assessment Instrument for Patients With Cancer and Concurrent Heart Failure. <i>Journal of Cardiac Failure</i> , 2008, 14, 497-507.	0.7	37
58	Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson symptom inventory, head and neck module. <i>Head and Neck</i> , 2007, 29, 923-931.	0.9	227
59	Asking the Community About Cutpoints Used to Describe Mild, Moderate, and Severe Pain. <i>Journal of Pain</i> , 2006, 7, 49-56.	0.7	102
60	Reliability and validity of a modified Brief Pain Inventory short form in patients with osteoarthritis. <i>European Journal of Pain</i> , 2006, 10, 353-353.	1.4	314
61	Lessons learned from a multiple-dose post-operative analgesic trial. <i>Pain</i> , 2004, 109, 103-109.	2.0	63
62	The Utility and Validity of the Modified Brief Pain Inventory in a Multiple-Dose Postoperative Analgesic Trial. <i>Clinical Journal of Pain</i> , 2004, 20, 357-362.	0.8	139
63	Assessing symptom distress in cancer patients. <i>Cancer</i> , 2000, 89, 1634-1646.	2.0	1,156
64	The rapid assessment of fatigue severity in cancer patients. <i>Cancer</i> , 1999, 85, 1186-1196.	2.0	1,482
65	When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. <i>Pain</i> , 1995, 61, 277-284.	2.0	1,265